Courts for years have given the FDA latitude to make judgments about health and safety based on scientific studies, but a challenge the justices hear Tuesday could set a precedent for courts to substitute their own conclusions for agency decisions.
Some legal experts believe if the Supreme Court agrees with an appeals court decision reversing FDA's expansion of mifepristone access, outside groups will seek out sympathetic judges to target contraception, certain vaccines or hormone therapies used in gender-affirming care.
[
add
]
[
|
|
...
]